Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …

Inhaled bronchodilator medications are central to the management of COPD and are
frequently given on a regular basis to prevent or reduce symptoms. While short-acting …

Introduction Chronic obstructive pulmonary disease (COPD) guidelines recommend
reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and …

Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive
pulmonary disease (COPD). However, there are limited data available on the response to …

Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …

The incidence of chronic obstructive pulmonary disease (COPD) is rising in the United
States, and the disease represents a significant source of morbidity and mortality. Primary …

Pharmacological medications used for the treatment of COPD patients have increased
significantly. Long-acting bronchodilators have been recognized as the mainstay of the …

This real-world study compared the effectiveness of triple therapy (TT; long-acting
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Purpose Randomized trials report that single-inhaler triple therapy is more effective than
dual bronchodilators at reducing exacerbations in patients with chronic obstructive …